Boston Scientific’s stronger margins contrast with softer product expectations, placing portfolio execution, restructuring, and medical-device innovation at the center of its outlook.
Procter & Gamble faces margin pressure despite stable revenue as productivity programs, cost inflation, brand strength, and cautious guidance shape its outlook.